OCGN Ocugen, Inc.
Price Chart
Executive Summary
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointment of Mohamed Genead, M.D., M.Sc., as Chief Medical Officer. All four stockholder proposals passed, including election of two Class III directors, ratification of PwC as auditor, and advisory approval of executive compensation on an annual frequency. The CMO appointment formalizes a role held on an interim basis since May 8, 2026 — no material business or financial implications.
Actionable Insight
Monitor next 10-Q for pipeline updates and cash runway; no immediate trading catalyst from this filing.
Key Facts
- Total of 139,628,075 shares of common stock represented at the Annual Meeting.
- Kirsten Castillo, MBA, and Satish Chandran, Ph.D. were elected as Class III directors until 2029.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026 with 136,784,245 votes for.
- Advisory say-on-pay approved with 49,968,948 for vs. 13,245,090 against (excluding broker non-votes).
- Stockholders selected a one-year frequency for future advisory votes on executive compensation.
- Mohamed Genead, M.D., M.Sc., appointed Chief Medical Officer effective June 11, 2026 (previously Acting/Interim CMO since May 8, 2026).
Financial Impact
No financial impact; administrative and governance actions only.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-073015 |
| Document: 0001104659-26-073015-index-headers.html | 0001104659-26-073015 |
| Document: 0001104659-26-073015-index.html | 0001104659-26-073015 |
| Document: 0001104659-26-073015.txt | 0001104659-26-073015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
8-K
| $1.22 awaiting T+20 | awaiting T+20 | — | $1.21 (−0.82%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $1.24 awaiting T+20 | awaiting T+20 | — | $1.21 (−2.02%) |
|
May 5, 2026
5w ago
|
8-K
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
May 5, 2026
5w ago
|
Press Release
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
May 5, 2026
5w ago
|
Press Release
| $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.21 (+18.79%) |
|
May 4, 2026
5w ago
|
8-K
| $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.21 (−18.79%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.21 (−27.98%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.21 (−36.98%) |
|
Mar 4, 2026
14w ago
|
8-K
| $1.96 $1.79 | ▼ −8.67% | ▼ −4.26% | $1.21 (−38.27%) |
|
Mar 4, 2026
14w ago
|
8-K
| $1.96 $1.79 | ▼ −8.67% | ▼ −4.26% | $1.21 (−38.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access